BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment... Show more
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule medicines for cancer treatment. The company, which trades on the Nasdaq Global Select Market under the symbol BLSM, went public in August 2026. Its most advanced candidate, BH-30643, is an OMNI-EGFR inhibitor being evaluated in the global Phase 1/2 SOLARA trial in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The company is also advancing BH-30236, a CLK inhibitor in Phase 1 testing for relapsed/refractory AML and HR-MDS, and BH-501284, a preclinical pan-KRAS program. Because BlossomHill generates no meaningful product revenue, investors follow the stock for its clinical data readouts, regulatory progress, and pipeline breadth.
Over the last 30 days, BLSM fell approximately 25.7%, declining from a closing price of $18.64 on September 30 to about $13.85 as of late October. The move reflects a sustained downward trend punctuated by elevated trading-volume sessions in mid-October.
The broader quarterly picture shows a more volatile trajectory. After pricing its IPO at $16.00 per share, BLSM rallied sharply, reaching a closing high of $26.82 on September 17 and an intraday high near $27.99 on September 21 — a gain of roughly 75% from the offering price. That advance has since reversed: shares now trade about 13% below their IPO price and roughly 48% below their mid-September closing peak.
The 30-day decline appears tied more to a reversal of post-IPO momentum than to a single widely reported company-specific negative event. After roughly doubling from its offering price, BLSM experienced a sharp correction as early gains were unwound, a pattern common among newly listed, thinly traded clinical-stage biotechs whose valuations are shaped by sentiment and technical flows rather than current fundamentals.
With no approved products and no material revenue, BlossomHill's share price is sensitive to shifts in risk appetite across the biotech sector. The absence of a fresh positive clinical catalyst during the period left the stock exposed to profit-taking, while elevated volume on down days signaled selling pressure as momentum faded. These dynamics help explain the magnitude of the pullback even without a discrete negative headline.
The quarter was defined by a rapid post-IPO run-up followed by a deep retracement. Initial enthusiasm around BlossomHill's oncology pipeline — particularly its differentiated OMNI-EGFR approach targeting C797S resistance in NSCLC — drove shares sharply higher through mid-September. As the rally extended, valuations stretched relative to the company's early-stage status, and the stock gave back most of its gains into late October.
The reversal underscores the two-sided nature of newly listed biotech equities: strong early demand can be followed by swift mean reversion when near-term catalysts are absent. Over the full period, BLSM ended below its $16.00 IPO price despite the interim surge, reflecting a normalization of valuation after an unusually rapid ascent.
Tickeron's Trending AI Robots page highlights a curated selection of top-performing AI trading bots from a broader platform that offers hundreds of bots trading thousands of tickers. Rather than listing every available strategy, the section surfaces the most relevant and consistently strong performers, spanning varied approaches, timeframes, and performance metrics. Because each bot differs in its strategy and risk profile, the page serves as a useful starting point for traders researching automated approaches across a wide range of securities. Those interested in exploring algorithmic trading tools can review the featured robots and their respective performance records directly on the page.
Looking ahead, BlossomHill's trajectory is likely to hinge on clinical and regulatory milestones. The company has stated it plans to seek an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026 regarding the recommended Phase 2 dose and a potential accelerated approval pathway for BH-30643 in C797S-positive EGFR-mutant NSCLC. Updated safety and efficacy data from the BH-30236 Phase 1 trial are expected in the first half of 2027, and an IND submission for BH-501284 is planned for the first quarter of 2027.
Investors should also monitor broader biotech market sentiment, which has been a meaningful driver of the stock's short-term moves. As always with clinical-stage companies, trial results, regulatory feedback, and financing conditions will be key variables shaping the stock's direction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology